Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis

被引:35
作者
Feng, Chen-chen [1 ]
Wang, Pao-hsun [3 ]
Ding, Qiang [1 ]
Guan, Ming [2 ]
Zhang, Yuan-fang [4 ]
Jiang, Hao-wen [1 ]
Wen, Hui [1 ]
Wu, Zhong [1 ]
机构
[1] Fudan Univ, Dept Urol, Huashan Hosp, Shanghai 200433, Peoples R China
[2] Fudan Univ, Cent Lab, Huashan Hosp, Shanghai 200433, Peoples R China
[3] Fudan Univ, Dept Surg, Huashan Hosp, Shanghai 200433, Peoples R China
[4] Fudan Univ, Huashan Hosp, Inst Urol, Shanghai 200433, Peoples R China
关键词
Angiogenesis; Bladder tumor; Tumor necrosis factor-alpha; Microvessel density; Pigment epithelium-derived factor; MICROVESSEL DENSITY; CELL-GROWTH; TNF-ALPHA; PEDF; CARCINOMA; CANCER; INSIGHTS; P53;
D O I
10.1016/j.urolonc.2010.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Angiogenesis is a pivotal process on which solid tumor growth is substantially dependent. Pigment epithelium-derived factor (PEDF) is the most potent natural anti-angiogenic factor, which has seldom been studied in bladder tumor, and whose functioning pathway remains unclear. We have thus investigated PEDF expression in relation to tumor necrosis factor-alpha (TNF-alpha) and microvessel density (MVD) with immunohistochemistry. Methods: Antibodies of PEDF and TNF-alpha were examined by Western blotting before immunohistochemistry. Sixty-four urothelial tumor sections and 23 normal controls were stained and expression of PEDF, TNF-alpha, and MVD were studied. Results: Decreased PEDF expression and increased TNF-alpha expression was noticed in tumorous tissue compared with healthy urothelium. Lower PEDF expression was related to higher tumor grade but stage. Increased TNF-alpha expression was noticed in recurrent, larger tumors as well as in tumors with progression in grade and stage. Expression of PEDF and TNF-alpha was correlated in bladder tumor. PEDF or TNF-alpha was correlated with MVD negatively or positively, respectively, in cancerous tissue and tumorous grouping without correlation in papillary urothelial neoplasm of low malignant potential. Conclusion: Expressional change of PEDF and TNF-alpha is in relation to angiogenesis of bladder tumor, especially in bladder cancer development. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 27 条
[1]  
[Anonymous], 2004, WHO CLASSIFICATION T
[2]  
BABJUK M, 2008, GUIDELINES TAT1 NONM, P3
[3]   ANGIOGENESIS IN BLADDER-CANCER - RELATIONSHIP BETWEEN MICROVESSEL DENSITY AND TUMOR PROGNOSIS [J].
BOCHNER, BH ;
COTE, RJ ;
WEIDNER, N ;
GROSHEN, S ;
CHEN, SC ;
SKINNER, DG ;
NICHOLS, PW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) :1603-1612
[4]  
Feng C, 2010, INT UROL NEPHROL
[5]   Characterization of PEDF: A Multi-Functional Serpin Family Protein [J].
Filleur, S. ;
Nelius, T. ;
de Riese, W. ;
Kennedy, R. C. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 106 (05) :769-775
[6]   Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice [J].
Gao, Y. ;
Yao, A. ;
Zhang, W. ;
Lu, S. ;
Yu, Y. ;
Deng, L. ;
Yin, A. ;
Xia, Y. ;
Sun, B. ;
Wang, X. .
ONCOGENE, 2010, 29 (19) :2784-2794
[7]   Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2 [J].
Guan, Ming ;
Jiang, Haowen ;
Xu, Chong ;
Xu, Rong ;
Chen, Zhongqing ;
Lu, Yuan .
CANCER BIOLOGY & THERAPY, 2007, 6 (03) :419-425
[8]   THE ANTITUMOR FUNCTION OF TUMOR NECROSIS FACTOR (TNF) .1. THERAPEUTIC ACTION OF TNF AGAINST AN ESTABLISHED MURINE SARCOMA IS INDIRECT, IMMUNOLOGICALLY DEPENDENT, AND LIMITED BY SEVERE TOXICITY [J].
HAVELL, EA ;
FIERS, W ;
NORTH, RJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) :1067-1085
[9]   Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components [J].
Ioachim, E. ;
Michael, M. C. ;
Salmas, M. ;
Damala, K. ;
Tsanou, E. ;
Michael, M. M. ;
Malamou-Mitsi, V. ;
Stavropoulos, N. E. .
BMC CANCER, 2006, 6 (1)
[10]  
JIANG H, 1992, J IMMUNOL, V149, P2137